2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1587

Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S
Abstract Number: 219

Contrast-Enhanced Ultrasound Of The Sovraortic Arteries: The Potential Role In Monitoring Disease Activity and Response To Treatment In Large Vessel Vasculitis
Abstract Number: 1249

Contrasting Pathophysiology and Behavioural Responses Associated With Osteoarthritis and An Inflammatory Arthropathy
Abstract Number: 567

Contribution Of Marginal Zone B Cells To Autoimmunity In The B6.Sle1.Sle2.Sle3 Lupus Prone Mouse
Abstract Number: 2502

Contributions Of Skin and Joint Manifestations To The Parent-Of-Origin Effect In Psoriatic Disease
Abstract Number: 343

Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
Abstract Number: 1357

Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs
Abstract Number: 2863

Copy Number Variations Of Complement C4A and C4B Genes Are Genetic Risk Factor and Disease Modification Factor, Respectively, For Juvenile Dermatomyositis
Abstract Number: 381

Coronary Endothelial Dysfunction Directly Measured By N13 Positron Emission Tomography (PET) Is Detected In Established Rheumatoid Arthritis (RA), But Not Early RA
Abstract Number: 954

Correlating The In Vivo Production Of IFNγ To Disease Parameters In TLR9-Induced Macrophage Activation Syndrome (MAS) In Mice
Abstract Number: 428

Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Abstract Number: 703

Correlation Between Patient Self-Report Of Symptoms Of Raynaud’s Phenomenon and Objective Assessment Of Digital Microvascular Perfusion Using Infrared Thermography
Abstract Number: 410

Correlation of Carotid Intima Media Thickness With Interleukin-6, Tumor Necrosis Factor-α and Anti-Cyclic Citrullinated Peptides In Rheumatoid Arthritis
Abstract Number: 2521

Correlation Of Anti Single and Double Stranded DNA Antibodies and Disease Activity In Systemic Lupus Erythematosus
Abstract Number: 2289

Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].